Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)

被引：0
|
作者：
Bendell, Johanna C. [1 ]
Rosen, Lee S. [2 ]
Mayer, Robert J. [3 ]
Goldman, Jonathan W. [2 ]
Infante, Jeffrey R. [1 ]
Benedetti, Fabio [4 ]
Lin, Donghu [5 ]
Mizuguchi, Hirokazu [4 ]
Zergebel, Christopher [4 ]
Patel, Manish R. [6 ]
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, 250 25th Ave North,Suite 200, Nashville, TN 37203 USA
[2] Univ Calif, 2020 Santa Monica Blvd,Suite 600, Santa Monica, CA 90404 USA
[3] Dana Farber Canc Inst, 450 Brookline Ave,Dana 1602, Boston, MA 02215 USA
[4] Taiho Oncol Inc, 202 Carnegie Ctr,Suite 100, Princeton, NJ 08540 USA
[5] Taiho Pharmaceut Beijing Co Ltd, 9F-9A3,Hanwei Plaza,7th,Guanghua Rd, Beijing 100004, Peoples R China
[6] Sarah Cannon Res Inst, Florida Canc Specialists, 600 N Cattlemen Rd,Suite 200, Sarasota, FL 34232 USA
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2016年 / 77卷 / 02期
关键词：
D O I：
10.1007/s00280-015-2890-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：439 / 439
页数：1
相关论文
共 50 条
  • [31] Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
    Jalali, A.
    Gard, G.
    Banks, S.
    Dunn, C.
    Wong, H. L.
    Wong, R.
    Lee, M.
    Gately, L.
    Loft, M.
    Shapiro, J. D.
    Kosmider, S.
    Tie, J.
    Ananda, S.
    Yeung, J. M.
    Jennens, R.
    Lee, B.
    McKendrick, J.
    Lim, L.
    Khattak, A.
    Gibbs, P.
    CURRENT PROBLEMS IN CANCER, 2022, 46 (02)
  • [32] Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Zhang, Wu
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Yang, Dongyun
    Berger, Martin D.
    West, Jordan David
    Ning, Yan
    Wakatsuki, Takeru
    Mashima, Tetsuo
    Okazaki, Satoshi
    Miyamoto, Yuji
    Hanna, Diana L.
    Marmorino, Federica
    Salvatore, Lisa
    Moretto, Roberto
    Borelli, Beatrice
    Barzi, Afsaneh
    Loupakis, Fotios
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
    Ishizaki, Tetsuo
    Mazaki, Junichi
    Enomoto, Masanobu
    Shigoka, Masatoshi
    Kasahara, Kenta
    Matsudo, Takaaki
    Kawakita, Hideaki
    Nagakawa, Yuichi
    Katsumata, Kenji
    Tsuchida, Akihiko
    ANTICANCER RESEARCH, 2021, 41 (04) : 2157 - 2163
  • [34] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [35] Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
    Hamauchi, S.
    Yamazaki, K.
    Masuishi, T.
    Kito, Y.
    Komori, A.
    Tsushima, T.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Muro, K.
    Yasui, H.
    Mori, K.
    Taniguchi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 50 - 51
  • [36] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
  • [37] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
    Hisamatsu, A.
    Ikusue, T.
    Toshima, H.
    Kobayashi, K.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer
    Yamazaki, K.
    Yoshino, T.
    Shinozaki, E.
    Komatsu, Y.
    Tsuji, Y.
    Nishina, T.
    Baba, H.
    Denda, T.
    Sugimoto, N.
    Tsuji, A.
    Yamaguchi, K.
    Takayama, T.
    Shimada, Y.
    Hamamoto, Y.
    Muro, K.
    Gotoh, M.
    Tanase, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals
    Beatriz, Gonzalez-Astorga
    Cebrian Irene, Gonzalez
    Ma Teresa, Delgado Urena
    Veronica, Conde
    Carmen, Sanchez-Toro
    Javier, Garcia-Garcia
    Encarnacion, Gonzalez-Flores
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
    Su, Guan-Li
    Wang, Yuan-Yuan
    Wang, Jin-Cheng
    Liu, Hao
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (07)
12345